Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.

Pestell, K E; Medlow, C J; Titley, J C; Kelland, L R; Walton, M I

Pestell, K E; Medlow, C J; Titley, J C; Kelland, L R; Walton, M I.

Affiliation

Pestell KE; CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Belmont Sutton, Surrey, UK. kathp@icr.ac.uk

Int J Cancer ; 77(6): 913-8, 1998 Sep 11.

Article in En | MEDLINE | ID: mdl-9714063

Subject(s)

Antineoplastic Agents/pharmacology; Carcinoma/metabolism; Cisplatin/pharmacology; Gene Expression Regulation, Neoplastic; Organoplatinum Compounds/pharmacology; Ovarian Neoplasms/metabolism; Proto-Oncogene Proteins c-bcl-2/metabolism; Tumor Suppressor Protein p53/metabolism; Blotting, Northern; Carcinoma/drug therapy; Carcinoma/genetics; Carcinoma/radiotherapy; DNA Primers; Female; Flow Cytometry; Humans; Immunoblotting; Ovarian Neoplasms/drug therapy; Ovarian Neoplasms/genetics; Ovarian Neoplasms/radiotherapy; Polymerase Chain Reaction; Tumor Cells, Cultured/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Organoplatinum Compounds / Ovarian Neoplasms / Carcinoma / Gene Expression Regulation, Neoplastic / Tumor Suppressor Protein p53 / Cisplatin / Proto-Oncogene Proteins c-bcl-2 / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Female / Humans Language: En Journal: Int J Cancer Year: 1998 Document type: Article Affiliation country: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links